Compare RC & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RC | PRTC |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.8M | 386.7M |
| IPO Year | N/A | N/A |
| Metric | RC | PRTC |
|---|---|---|
| Price | $2.24 | $16.91 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.75 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 4.8K |
| Earning Date | 11-06-2025 | 08-28-2025 |
| Dividend Yield | ★ 20.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $6,391,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $32.94 | N/A |
| P/E Ratio | ★ N/A | $7.77 |
| Revenue Growth | N/A | ★ 1265.60 |
| 52 Week Low | $2.32 | $13.30 |
| 52 Week High | $7.64 | $23.35 |
| Indicator | RC | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 30.43 | 51.09 |
| Support Level | $2.37 | $16.44 |
| Resistance Level | $2.53 | $17.17 |
| Average True Range (ATR) | 0.13 | 0.35 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 3.45 | 55.29 |
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.